GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Gross Profit

RUA Life Sciences (FRA:AOHA) Gross Profit : €1.75 Mil (TTM As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Gross Profit?

RUA Life Sciences's gross profit for the six months ended in Sep. 2023 was €0.71 Mil. RUA Life Sciences's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was €1.75 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. RUA Life Sciences's gross profit for the six months ended in Sep. 2023 was €0.71 Mil. RUA Life Sciences's Revenue for the six months ended in Sep. 2023 was €0.92 Mil. Therefore, RUA Life Sciences's Gross Margin % for the quarter that ended in Sep. 2023 was 77.52%.

RUA Life Sciences had a gross margin of 77.52% for the quarter that ended in Sep. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of RUA Life Sciences was 83.57%. The lowest was 81.94%. And the median was 82.19%.


RUA Life Sciences Gross Profit Historical Data

The historical data trend for RUA Life Sciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Gross Profit Chart

RUA Life Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.55 1.46 1.63 2.03

RUA Life Sciences Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.99 1.00 1.04 0.71

Competitive Comparison of RUA Life Sciences's Gross Profit

For the Medical Devices subindustry, RUA Life Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RUA Life Sciences's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Gross Profit falls into.



RUA Life Sciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

RUA Life Sciences's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=2.47 - 0.44
=2.03

RUA Life Sciences's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0.921 - 0.207
=0.71

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.75 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

RUA Life Sciences's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.71 / 0.921
=77.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


RUA Life Sciences  (FRA:AOHA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

RUA Life Sciences had a gross margin of 77.52% for the quarter that ended in Sep. 2023 => Durable competitive advantage


RUA Life Sciences Gross Profit Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences (FRA:AOHA) Business Description

Traded in Other Exchanges
Address
2 Drummond Crescent, Scotland, Irvine, Ayrshire, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.

RUA Life Sciences (FRA:AOHA) Headlines

No Headlines